Development and evaluation of orally disintegrating tablets of cilostazol-β-cyclodextrin inclusion complexes

References

• Brook R, Weder A, Grossman M, Rajagopalan S. Management of intermittent claudication. Cardiol Clin 2002;20:521–34
   PubMedGoogle Scholar
• Meru A, Mittra S, Chugh A. Intermittent claudication: an overview. Atherosclerosis 2006;187:221–37
   PubMed Web of Science ®Google Scholar
• Rowlands T, Donnelly R. Medical therapy for intermittent claudication. Eur J Vasc Endovasc Surg 2007;34:314–21
   PubMed Web of Science ®Google Scholar
• Okazaki H, Kamada N, Toda M, et al. An orally disintegrating tablet. WO 2009/107864 A2, February 26, 2009
   Google Scholar
• Murata K, Kameyama M, Fukui F, et al. Phosphodiesterase type III inhibitor, cilostazol, inhibits colon cancer cell motility. Clin Exp Metastasis 1999;17:525–30
   PubMed Web of Science ®Google Scholar
• Chi W, Milani R, White C. Safety and efficacy of cilostazol in the management of intermittent claudication. Vasc Health Risk Manag 2008;4:1197–203
   PubMedGoogle Scholar
• Bramer S, Forbes W, Mallikaarjun S. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease. Clin Pharmacokinet 1999;37:1–11
   PubMed Web of Science ®Google Scholar
• Davis M, Brewster M. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov 2004;3:1023–35
   PubMed Web of Science ®Google Scholar
• Jadhav A, Pathare D, Shingare M. A validated stability indicating high performance reverse phase liquid chromatographic method for the determination of cilostazol in bulk drug substance. Drug Dev Ind Pharm 2007;33:173–9
   PubMed Web of Science ®Google Scholar
• Pandit V, Gorantla R, Sarasija S. Preparation and characterization of pioglitazone cyclodextrin inclusion complexes. J Young Pharm 2011;3:267–74
   PubMedGoogle Scholar
• Higuchi T, Connors KA. Phase solubility techniques. In: Reiley CN, ed. Advances in analytical chemistry and instrumentation. New York: Interscience; 1965:117–212
   Google Scholar
• Jobs P. Formation and stability of inorganic complexes in solution. Justus Liebigs Ann Chem 1928;9:113–203
   Google Scholar
• Patel AR, Vavia PR. Preparation and evaluation of taste masked famotidine formulation using drug/β-cyclodextrin/polymer ternary complexation approach. AAPS PharmSciTech 2008;9:544–50
   PubMed Web of Science ®Google Scholar
• Berman HM, Westbrook J, Feng J, et al. The protein data bank. Nucleic Acids Res 2000;28:235–42
   PubMed Web of Science ®Google Scholar
• Mark P, Nilsson L. Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K. J Phys Chem A 2001;105:9954–60
   Web of Science ®Google Scholar
• Chadha R, Gupta S, Pissurlenkar RRS, Coutinho EC. Characterization, thermodynamic parameters, molecular modeling and in vivo studies of inclusion complexes of pyrimethamine with native β-cyclodextrin and its derivatives. Int J Pharm Pharm Sci 2001;4:102–12
   Google Scholar
• Jeong SH, Lee J, Woo JS. Fast disintegrating tablets. In: Wen H, Park K, eds. Oral controlled release formulation design and drug delivery: theory to practice. New Jersey: John Wiley & Sons, Inc.; 2010:117–212
   Google Scholar
• Latinen R, Suikho E, Bjorkqvist M, et al. Perphenazine solid dispersions for orally fast-disintegrating tablets: physical stability and formulation. Drug Dev Ind Pharm 2010;36:601–13
   PubMed Web of Science ®Google Scholar
• Pabari RM, Ramtoola Z. Effect of a disintegration mechanism on wetting, water absorption, and disintegration time of orodispersible tablets. J Young Pharm 2012;4:157–63
   PubMedGoogle Scholar
• Zhou HJ, Jiang LJ, Zhang YP, Li JB. β-Cyclodextrin inclusion complex: preparation, characterization, and its aspirin release in vitro. Front Mater Sci 2012;6:259–67
   Web of Science ®Google Scholar
• Morin N, Chilouet A, Millet J, Rouland JC. Bifonazole-β-cyclodextrin inclusion complexes. Thermal analysis and X-ray powder diffraction study. J Therm Anal Calorim 2000;62:187–201
   Web of Science ®Google Scholar
• Tayade PT, Vavia PR. Inclusion complexes of Ketoprofen with β-cyclodextrins: oral pharmacokinetics of Ketoprofen in human. Indian J Pharm Sci 2006;68:164–70
   Google Scholar
• Pund S, Shete Y, Jagadale S. Multivariate analysis of physicochemical characteristics of lipid based nanoemulsifying cilostazol – quality by design. Colloids Surf B Biointerfaces 2014;115:29–36
   PubMed Web of Science ®Google Scholar
• Late SG, Banga AK. Response surface methodology to optimize novel fast disintegrating tablets using β cyclodextrin as diluents. AAPS PharmSciTech 2010;11:1627–35
   PubMed Web of Science ®Google Scholar
• Malakar J, Nayak AK, Goswami S. Use of response surface methodology in the formulation and optimization of bisoprolol fumarate matrix tablets for sustained drug release. ISRN Pharm 2012;2012:1–10
   Google Scholar
• Loftsson T, Hreinsdottir D, Masson M. Evaluation of cyclodextrin solubilization of drugs. Int J Pharm 2005;302:18–28
   PubMed Web of Science ®Google Scholar
• Loftsson T, Magnusdottir A, Masson M, Sigurjonsdottir JF. Self-association and cyclodextrin solubilization of drugs. J Pharm Sci 2002;91:2307–16
   PubMed Web of Science ®Google Scholar
• Goyal G, Vavia PR. Complexation approach for fixed dose tablet formulation of lopinavir and ritonavir: an anamolous relationship between stability constant, dissolution rate and saturation solubility. J Incl Phenom Macrocycl Chem 2012;73:75–85
   Web of Science ®Google Scholar
• Sambasevam KP, Mohamad S, Sarih NM, Ismail N. Synthesis and characterization of the inclusion complex of β-cyclodextrin and azomethine. Int J Mol Sci 2013;14:3671–82
   PubMed Web of Science ®Google Scholar
• Mura P, Adragna E, Rabasco AM, et al. Effect of host cavity size and the preparation method on the physicochemical properties of ibuproxam-cyclodextrin. Drug Dev Ind Pharm 1999;25:279–87
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Vavia PR, Trotta F, et al. Structural evidence of differential forms of nanosponges of beta-cyclodextrin and its effect on solubilization of a model drug. J Incl Phenom Macrocycl Chem 2013;76:201–11
   Web of Science ®Google Scholar
• Wang S, Ding Y, Yao Y. Inclusion complexes of fluorofenidone with beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin. Drug Dev Ind Pharm 2009;35:808–13
   PubMed Web of Science ®Google Scholar
• Upadhyay SK, Kumar G. NMR and molecular modelling studies on the interaction of fluconazole with β-cyclodextrin. Chem Cent J 2009;3:1–13
   PubMed Web of Science ®Google Scholar
• Perez-Cruz F, Julian C, Rodrigues J, et al. Molecular encapsulation of 5-nitroindazole derivatives in 2,6-dimethyl-β-cyclodextrin: electrochemical and spectroscopic studies. Bioorg Med Chem 2009;17:4604–11
   PubMed Web of Science ®Google Scholar
• Shah MR, Sancheti PP, Vyas VM, et al. Proton magnetic resonance (1HNMR) spectroscopy and physicochemical studies of zaleplon-hydroxypropyl-β-cyclodextrin inclusion compounds. Drug Discov Ther 2010;4:70–6
   PubMedGoogle Scholar
• Zeng F, Wang L, Zhang W, et al. Formulation and in vivo evaluation of orally disintegrating tablets of clozapine/hydroxypropyl-β-cyclodextrin inclusion complexes. AAPS PharmSciTech 2013;14:854–60
   PubMed Web of Science ®Google Scholar
• Sheshala R, Khan N, Darwis Y. Formulation and optimization of orally disintegrating tablets of sumatriptan succinate. Chem Pharm Bull 2011;59:920–8
   PubMed Web of Science ®Google Scholar
• Abed KK, Hussein AA, Ghareeb MM, Abdulrasool AA. Formulation and optimization of orodispersible tablets of diazepam. AAPS PharmSciTech 2010;11:356–61
   PubMed Web of Science ®Google Scholar
• Wang L, Zeng F, Zong, L. Development of orally disintegrating tablets of perphenazine/hydroxypropoyl-β-cyclodextrin inclusion complex. Pharm Dev Technol 2013;18:1101–10
   PubMed Web of Science ®Google Scholar
• Hulse WL, Forbes RT, Bonner MC, Getrost M. The characterization and comparison of spray-dried mannitol samples. Drug Dev Ind Pharm 2009;35:712–18
   PubMed Web of Science ®Google Scholar
• Westermarck S, Juppo AM, Kervinen L, Yliruusi J. Microcrystalline cellulose and its microstructure in pharmaceutical processing. Eur J Pharm Biopharm 1999;48:199–206
   PubMed Web of Science ®Google Scholar
• Chaudhary H, Gauri S, Rathee P, Kumar V. Development and optimization of fast dissolving oro-dispersible films of granisetron HCl using Box–Behnken statistical design. Bul Faculty Pharm, Cairo University 2013;51:193–201
   Google Scholar
• Rahman Z, Siddiqui A, Khan MA. Orally disintegrating tablet of novel salt of antiepileptic drug: formulation strategy and evaluation. Eur J Pharm Biopharm 2013;85:1300–9
   PubMed Web of Science ®Google Scholar